ALX Oncology Holdings Inc.


By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Its lead product candidate under development, ALX148, is a next-generation CD47 blocking therapeutic for the treatment of first-line head and neck cancer and second-line gastric/gastroesophageal junction cancer and breast cancer.

Contact Information

Main Phone: +1 650 466-7125
Address: 866 Malcolm Road
Address 2: Suite 100
State: CA
City / Town: Burlingame
Country: US
Postal Code: 94010

Issuer Information

Exchange: NGS
CEO: Jaume Pons
Employees: 23
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A